Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-05-06 19:40:04 ET · period of report 2026-05-04 · accession 0001798679-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-05-06 19:40 | 2026-05-04 | ARQT | Matsuda Masaru | See Remarks | S - Sale | $23.31 | -8,256 | 126.7K | -6% | -$192.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-04 | S | D | 7,372 | $23.27 | 127,573 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.1167 to $23.48, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Due to a scrivener's error on the Reporting Person's Form 4 filed on March 3, 2026, the number of shares of common stock beneficially owned by the Reporting Person reflected a discrepancy that inadvertently overstated the Reporting Person's beneficial ownership by 1,987 shares. The correct number of shares beneficially owned by the Reporting Person is reflected in this Form 4. |
| 2 | Common | Common Stock | 2026-05-04 | S | D | 884 | $23.61 | 126,689 | D | — | — | (F4) The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. (F5) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |